Cladribine tablets –
a potential new short-course oral therapy in MS

Friday 11 September 2009, 18:00–19:00
Main Auditorium, Hall 1, CCD Süd
Congress Center Düsseldorf
Düsseldorf, Germany
Dear Colleague

I am delighted to invite you to Düsseldorf for ECTRIMS 2009 and to the symposium, Cladribine tablets – a potential new short-course oral therapy in MS, which will be held on Friday 11 September from 18:00 to 19:00.

This is an exciting time in the treatment of MS for clinicians and patients alike; a number of therapies boasting new mechanisms of targeting the disease as well as new routes of administration are currently on the horizon. In addition to hopefully increased efficacy, the introduction of oral treatments will relieve the burden of patients needing to inject their MS therapy and should offer enhanced convenience. Easier administration may improve patient adherence to treatment, which, along with greater efficacy, can impact positively on clinical outcomes.

We can look forward to some engaging presentations surrounding the compelling data that has recently emerged from the Phase III CLARITY study of cladribine tablets in relapsing-remitting MS. In particular, we plan to examine the key efficacy, safety and tolerability data from this study, as well as to use lessons from the CLARITY data to illustrate how success in the treatment of MS may be optimised by treating patients on a more individual basis. Our speakers are global experts in the field of MS and I am sure they will provide us with some valuable insights into the data and its relevance for the disease.

I hope that you will be able to join us and look forward to meeting you for what promises to be a very interesting symposium. Many thanks in advance for your attention and input.

F. Heidenreich

Fedor Heidenreich
Department of Neurology and Clinical Neurophysiology
Diakoniekrankenhaus Henriettenstiftung
Hannover, Germany
Cladribine tablets –
a potential new short-course oral therapy in MS

Friday 11 September 2009, 18:00–19:00

Chair: Fedor Heidenreich, Germany

18:00   Introduction
        Fedor Heidenreich, Germany

18:05   Efficacy outcomes with cladribine tablets
        Gavin Giovannoni, UK

18:20   Safety and tolerability of cladribine tablets
        Stuart Cook, USA

18:35   Optimising success in MS treatment
        Peter Rieckmann, Germany /Canada

18:50   Wrap up and Q&A
        Fedor Heidenreich, Germany